Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies-Reference-Cited by-同舟云学术

Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies

Published:2017-05-26 Issue:1 Volume:8 Page:
ISSN:2041-1723
Container-title:Nature Communications
language:en
Short-container-title:Nat Commun

Author:

San José-Enériz Edurne,Agirre Xabier,Rabal Obdulia,Vilas-Zornoza Amaia,Sanchez-Arias Juan A.,Miranda Estibaliz,Ugarte Ana,Roa Sergio^ORCID,Paiva Bruno,Estella-Hermoso de Mendoza Ander,Alvarez Rosa María,Casares Noelia,Segura Victor,Martín-Subero José I.,Ogi François-Xavier,Soule Pierre,Santiveri Clara M.,Campos-Olivas Ramón,Castellano Giancarlo,de Barrena Maite Garcia Fernandez,Rodriguez-Madoz Juan Roberto^ORCID,García-Barchino Maria José,Lasarte Juan Jose,Avila Matias A,Martinez-Climent Jose Angel,Oyarzabal Julen,Prosper Felipe

Publisher

Springer Science and Business Media LLC

Subject

General Physics and Astronomy,General Biochemistry, Genetics and Molecular Biology,General Chemistry

Link

http://www.nature.com/articles/ncomms15424.pdf

Reference37 articles.

1. Helin, K. & Dhanak, D. Chromatin proteins and modifications as drug targets. Nature 502, 480–488 (2013).

2. Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K. & Schapira, M. Epigenetic protein families: a new frontier for drug discovery. Nat. Rev. Drug Discov. 11, 384–400 (2012).

3. Lane, A. A. & Chabner, B. A. Histone deacetylase inhibitors in cancer therapy. J. Clin. Oncol. 27, 5459–5468 (2009).

4. Issa, J. P. & Kantarjian, H. M. Targeting DNA methylation. Clin. Cancer Res. 15, 3938–3946 (2009).

5. McGrath, J. & Trojer, P. Targeting histone lysine methylation in cancer. Pharmacol. Ther. 150, 1–22 (2015).

Cited by 121 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transcripts of repetitive DNA elements signal to block phagocytosis of hematopoietic stem cells;Science;2024-09-13

2. Structure-based development of novel substrate-type G9a inhibitors as epigenetic modulators for sickle cell disease treatment;Bioorganic & Medicinal Chemistry Letters;2024-09

3. GLP and G9a histone methyltransferases as potential therapeutic targets for lymphoid neoplasms;Cancer Cell International;2024-07-12

4. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia;Nature Communications;2024-07-02

5. KDM1A, a potent and selective target, for the treatment of DNMT3A-deficient non-small cell lung cancer;British Journal of Cancer;2024-06-29